20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter Binding

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 3, 2016, Pages 525-533

  Garcia, Victor ^a   Shkolnik, Brian ^a   Milhau, Laura ^b   Falck, John R ^c   Schwartzman, Michal Laniado ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXY 6,15 EICOSADIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; I KAPPA B; I KAPPA B KINASE BETA; I KAPPA B KINASE BETA INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; HYDROXYICOSATETRAENOIC ACID; PROTEIN BINDING;

ARTICLE; BINDING SITE; CAPILLARY ENDOTHELIAL CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION INITIATION; CELL CULTURE; DRUG EFFECTS; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY;

CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; NF-KAPPA B; PEPTIDYL-DIPEPTIDASE A; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION, GENETIC;

EID: 84958953923     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.229377     Document Type: Article

References (47)

1. Akbulut T, Regner KR, Roman RJ, Avner ED, Falck JR, and Park F (2009) 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFRand c-Src-dependent mechanism. Am J Physiol Renal Physiol 297:F662-F670.
2. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, Shen XZ, Fuchs S, and Touyz RM (2013) A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65:1-46.
3. Bernstein KE, Xiao HD, Frenzel K, Li P, Shen XZ, Adams JW, and Fuchs S (2005) Six truisms concerning ACE and the renin-Angiotensin system educed from the genetic analysis of mice. Circ Res 96:1135-1144.
4. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, and Francis J (2012) Angiotensin II-induced hypertension is modulated by nuclear factor-kBin the paraventricular nucleus. Hypertension 59:113-121.
5. Cheng J, Garcia V, Ding Y, Wu CC, Thakar K, Falck JR, Ramu E, and Schwartzman ML (2012) Induction of angiotensin-converting enzyme and activation of the reninangiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol 32:1917-1924.
6. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, Jr., and Schwartzman ML (2008) 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 294: H1018-H1026.
7. Cheng J, Wu CC, Gotlinger KH, Zhang F, Narsimhaswamy D, Falck JR, and Schwartzman ML (2009) 20-Hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 332:57-65.
8. Duh EJ, Maury WJ, Folks TM, Fauci AS, and Rabson AB (1989) Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 86:5974-5978.
9. Eyries M, Agrapart M, Alonso A, and Soubrier F (2002) Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human endothelial cells via ERK1/2 pathway. Circ Res 91:899-906.
10. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, Engström G, Berglund G, Minuz P, and Melander O (2008) The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52:373-380.
11. Fuchs S, Xiao HD, Hubert C, Michaud A, Campbell DJ, Adams JW, Capecchi MR, Corvol P, and Bernstein KE (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51:267-274.
12. Gallagher PE, Li P, Lenhart JR, Chappell MC, and Brosnihan KB (1999) Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33:323-328.
13. Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJ, and Scicli AG (2007) Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 321:18-27.
14. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, and Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132-140.
15. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, and Luft FC, et al. (2007) Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res 101:268-276.
16. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, and Egido J (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532-1541.
17. Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, and Laniado-Schwartzman M (2008) 20-Hydroxyeicosatetraenoic acid stimulates nuclear factorkappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 324:103-110.
18. Kassan M, Choi SK, Galán M, Bishop A, Umezawa K, Trebak M, Belmadani S, and Matrougui K (2013) Enhanced NF-kB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes. Diabetes 62:2078-2087.
19. Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, and Christians U, et al. (2013) Bioactive lipid mediators in polycystic kidney disease. J Lipid Res 55:1139-1149.
20. Liu H, Zhao Y, Nie D, Shi J, Fu L, Li Y, Yu D, and Lu J (2008) Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol 19:714-721.
21. Mehta PK and Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97.
22. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, and Busse R (2003) Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17:770-772.
23. Miyata N and Roman RJ (2005) Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41:175-193.
24. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, and Haller H, et al. (2000) NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35:193-201.
25. Mungunsukh O, Marquez AP, Lee YH, Thiel G, and Day RM (2008) Characterization of the bovine angiotensin converting enzyme promoter: essential roles of Egr-1, ATF-2 and Ets-1 in the regulation by phorbol ester. Gene 421:81-88.
26. Ng KK and Vane JR (1967) Conversion of angiotensin I to angiotensin II. Nature 216: 762-766.
27. Okada H (2012) A look at transactivation of the EGF receptor by angiotensin II. J Am Soc Nephrol 23:183-185.
28. Panigrahy D, Kaipainen A, Greene ER, and Huang S (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 29:723-735.
29. Ramchandran R, Sen GC, Misono K, and Sen I (1994) Regulated cleavage-secretion of the membrane-bound angiotensin-converting enzyme. J Biol Chem 269:2125-2130.
30. Rieder MJ, Carmona R, Krieger JE, Pritchard KA, Jr., and Greene AS (1997) Suppression of angiotensin-converting enzyme expression and activity by shear stress. Circ Res 80:312-319.
31. Savoia C and Schiffrin EL (2006) Inflammation in hypertension. Curr Opin Nephrol Hypertens 15:152-158.
32. Shai SY, Langford KG, Martin BM, and Bernstein KE (1990) Genomic DNA 59 to the mouse and human angiotensin-converting enzyme genes contains two distinct regions of conserved sequence. Biochem Biophys Res Commun 167:1128-1133.
33. Shen XZ, Xiao HD, Li P, Lin CX, Billet S, Okwan-Duodu D, Adams JW, Bernstein EA, Xu Y, and Fuchs S, et al. (2008) New insights into the role of angiotensinconverting enzyme obtained from the analysis of genetically modified mice. J Mol Med 86:679-684.
34. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, and Schwartzman ML (2007) Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50:123-129.
35. Singh H and Schwartzman ML (2008) Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep 60:29-37.
36. Skidgel RA and Erdös EG (1987) The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A 9:243-259.
37. Sodhi K, Wu CC, Cheng J, Gotlinger K, Inoue K, Goli M, Falck JR, Abraham NG, and Schwartzman ML (2010) CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid-And angiotensin II-dependent. Hypertension 56:871-878.
38. Villard E, Alonso A, Agrapart M, Challah M, and Soubrier F (1998) Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J Biol Chem 273:25191-25197.
39. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, and Nasjletti A, et al. (2006) Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 98:962-969.
40. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, and Croft KD (2005) Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 38:1032-1036.
41. Ward NC, Rivera J, Hodgson J, Puddey IB, Beilin LJ, Falck JR, and Croft KD (2004) Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110:438-443.
42. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, and Croft KD (2008) A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 51:1393-1398.
43. Wu CC, Cheng J, Zhang FF, Gotlinger KH, Kelkar M, Zhang Y, Jat JL, Falck JR, and Schwartzman ML (2011) Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kappaB kinase. Hypertension 57:788-794.
44. Wu CC, Gupta T, Garcia V, Ding Y, and Schwartzman ML (2014) 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 22:1-12.
45. Xavier-Neto J, Pereira AC, Junqueira ML, Carmona R, and Krieger JE (1999) Rat angiotensin-converting enzyme promoter regulation by beta-Adrenergics and cAMP in endothelium. Hypertension 34:31-38.
46. Yan G, Chen S, You B, and Sun J (2008) Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res 78:308-314.
47. Zeng Q, Han Y, Bao Y, Li W, Li X, Shen X, Wang X, Yao F, O'Rourke ST, and Sun C (2010) 20-HETE increases NADPH oxidase-derived ROS production and stimulates L-type calcium channel via PKC-dependent mechanism in cardiomyocytes. Am J Physiol Heart Circ Physiol 299:H1109-H1117.